Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer

Published:2016-11 Issue:11 Volume:11 Page:2027-2032
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lin Jessica J.,Kennedy Elizabeth,Sequist Lecia V.,Brastianos Priscilla K.,Goodwin Kelly E.,Stevens Sara,Wanat Alexandra C.,Stober Lisa L.,Digumarthy Subba R.,Engelman Jeffrey A.,Shaw Alice T.,Gainor Justin F.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

2. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N Engl J Med,2014

3. Novel targets in non-small cell lung cancer: ROS1 and RET fusions;Gainor;Oncologist,2013

4. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer;Wang;J Clin Oncol,2012

5. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas;Drilon;Cancer Discov,2013

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

2. Non–Small Cell Lung Cancer, Version 4.2024;Journal of the National Comprehensive Cancer Network;2024-05

3. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations;Journal of Medicinal Chemistry;2024-03-14

4. Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer;Heliyon;2024-01

5. Lung Cancer;Biomedical Aspects of Solid Cancers;2024